Effects of IFN-γ and interleukin-1β on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: Relevance to its cytolysis by alloreactive cytotoxic T lymphocytes

Journal of Interferon and Cytokine Research

Volumn 22, Issue 12, 2002, Pages 1209-1216

  Schiltz, Patric M ^a,b   Gomez, German G ^a   Read, Susana B ^a   Kulprathipanja, Nisha V ^a   Kruse, Carol A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT INTERLEUKIN 1BETA; T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; GLIOSARCOMA; IMMUNOTHERAPY; MIXED LYMPHOCYTE REACTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; TUMOR CELL DESTRUCTION;

ANIMALS; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; GLIOSARCOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-1; ISOANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; RATS; RATS, INBRED F344; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0036977371     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900260475731     Document Type: Article

References (44)

1. PRADOS, M.D., BERGER, M.S., and WILSON, C.B. (1998). Primary central nervous system tumors: advances in knowledge and treatment. CA 48, 331-360.
2. KRUSE, C.A., LILLEHEI, K.O., MITCHELL, D.H., KLEINSCHMIDT-DEMASTERS, B.K., and BELLGRAU, D. (1990). Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc. Natl. Acad. Sci. USA 87, 9577-9581.
3. FLESHNER, M., WATKINS, L.R., REDD, J.M., KRUSE, C.A., and BELLGRAU, D. (1992). A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplant 1, 307-312.
4. KRUSE, C.A., MITCHELL, D.H., KLEINSCHMIDT-DEMASTERS, B.K., BELLGRAU, D., EULE, J.M., PARRA, J.R., KONG, Q., and LILLEHEI, K.O. (1993). Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J. Neurooncol. 15, 97-112.
5. KRUSE, C.A., SCHILTZ, P.M., BELLGRAU, D., KONG, Q., and KLEINSCHMIDT-DEMASTERS, B.K. (1994). Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J. Neurooncol. 19, 161-168.
6. KRUSE, C.A., CEPEDA, L., OWENS, B., JOHNSON, S.D., STEARS, J., and LILLEHEI, K.O. (1997). Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45, 77-87.
7. KRUSE, C.A., and RUBINSTEIN, D. (2001). Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors. In: Brain Tumor Immunotherapy. L.M. Liau, D.P. Becker, T.F. Cloughesy, and D.D. Bigner (eds.). Totowa, NJ: Humana Press, pp. 149-170.
8. FABRE, J.W. (2001). The allogeneic response and tumor immunity. Nat. Med. 7, 649-652.
9. VIRASCH, N.K., and KRUSE, C.A. (2001). Strategies using the immune system for therapy of brain tumors. Hematol. Oncol. Clin. North Am. 15, 1053-1071.
10. EGGERS, A.E., TARMIN, L., and GAMBOA, E.T. (1985). In vivo immunization against autologous glioblastoma-associated antigens. Cancer Immunol. Immunother. 19, 43-45.
11. LAMPSON, L.A., and HICKEY, W.F. (1986). Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J. Immunol. 136, 4054-4062.
12. SUCHIN, E.J., LANGMUIR, P.B., PALMER, E., SAYEGH, M.H., WELLS, A.D., and TURKA, L.A. (2001). Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166, 973-981.
13. KRUSE, C.A., and BECK, L.T. (1997). Artificial capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotechnol. Appl. Biochem. 25, 197-205.
14. LARSON, R.S., CORBI, A.L., BERMAN, L., and SPRINGER, T. (1989). Primary structure of the leukocyte function-associated molecule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily. J. Cell Biol. 108, 703-712.
15. MAKGOBA, M., SANDERS, M., GINTHER-LUCE, G., GUGEL, E., DUSTIN, M., SPRINGER, T., and SHAW, S. (1988). Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1 dependent adhesion in T cell-mediated cytotoxicity. Eur. J. Immunol. 18, 637-640.
16. COULDWELL, W.T., DE TRIBOLET, N., ANTEL, J.P., GAUTHIER, T., and KUPPNER, M.C. (1992). Adhesion molecules and malignant gliomas: implications for tumorigenesis. J. Neurosurg. 76, 782-791.
17. KURZINGER, K., REYNOLDS, T., GERMAIN, R.N., DAVIGNON, D., MARTZ, E., and SPRINGER, T.A. (1981). A novel lymphocyte function-associated antigen (LFA-1): cellular distribution, quantitative expression, and structure. J. Immunol. 127, 596-602.
18. GROSS, N., FAVRE, S., BECK, D., and MEYER, M. (1992). Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants. Int. J. Cancer 52, 85-91.
19. KUPPNER, M.C., VAN MEIR, E., HAMOU, M.F., and DE TRIBOLET, N. (1990). Cytokine regulation of intercellular adhesion molecule-1 (ICAM-1) expression on human glioblastoma cells. Clin. Exp. Immunol. 81, 142-148.
20. ROTH, W., and WELLER, M. (1999). Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell. Mol. Life Sci. 56, 481-506.
21. GUARINI, L., TEMPONI, M., BRUCE, J.N., BOLLON, A.P., DUIGOU, G.J., MOULTON, T.A., FERRONE, S., and FISHER, P.B. (1990). Expression and modulation by cytokines of the intercellular adhesion molecule-1 (ICAM-1) in human central nervous system tumor cell cultures. Int. J. Cancer 46, 1041-1047.
22. AKBASAK, A., OLDFIELD, E.H., and SARIS, S.C. (1991). Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J. Neurosurg. 75, 922-929.
23. GALANDRINI, R., ALBI, N., SARCONE, D., GROSSI, C.E., and VELARDI, A. (1992). Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. Eur. J. Immunol. 22, 2047-2053.
24. ZARCONE, D., VIALE, O., CERRUTI, G., TENCA, C., MALORNI, W., ARANCIA, G., IOSI, F., GALANDRINI, R., VELARDI, A., and MORETTA, A. (1992). Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation. Cell. Immunol. 143, 389-404.
25. PERUSSIA, B., MANGONI, L., ENGERS, H.D., and TRINCHIERI, G. (1980). Interferon production by human and murine lymphocytes in response to alloantigens. J. Immunol. 125, 1589-1595.
26. BOEHM, U., KLAMP, T., GROOT, M., and HOWARD, J.C. (1997). Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15, 749-795.
27. SETHNA, M.P., and LAMPSON, L.A. (1991). Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma. J. Neuroimmunol. 34, 121-132.
28. WEN, P.Y., LAMPSON, M.A., and LAMPSON, L.A. (1992). Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J. Neuroimmunol. 36, 57-68.
29. DUSTIN, M.L., ROTHLEIN, R., BHAN, A.K., DINARELLO, C.A., and SPRINGER, T.A. (1986). Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137, 245-254.
30. REDD, J.M., LAGARDE, A.C., KRUSE, C.A., and BELLGRAU, D. (1992). Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 34, 349-354.
31. NATALI, P.G., BIGOTTI, A., NICOTRA, M.R., VIORA, M., MANFREDI, D., and FERRONE, S. (1984). Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res. 44, 4679-4687.
32. BIGNER, D.D., BIGNER, S.H., PONTEN, J., WESTERMARK, B., MAHALEY, M.S., RUOSLAHTI, E., HERSCHMAN, H., ENG, L.F., and WIKSTRAND, C.J. (1981). Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 40, 201-229.
33. KUPPERS, R.C., BALLAS, Z.K., GREEN, W.R., and HENNEY, C.S. (1981). Quantitative appraisal of H-2 products in T cell-mediated lysis by allogeneic and syngeneic effector cells. J. Immunol. 127, 500-504.
34. THIEME, T.R., HEFENEIDER, S.H., WAGNER, C.R., and BURGER, D.R. (1987). Recombinant murine and human IL-1 alpha bind to human endothelial cells with an equal affinity, but have an unequal ability to induce endothelial cell adherence of lymphocytes. J. Immunol. 139, 1173-1178.
35. LIU, C., BAI, Y., GANEA, D., and HART, R.P. (1995). Species-specific activity of rat recombinant interleukin-1β. J. Interferon Cytokine Res. 15, 985-992.
36. ANFORTH, H.R., BLUTHE, R.M., BRISTOW, A., HOPKINS, S., LENCZOWSKI, M.J., LUHESHI, G., LUNDKVIST, J., MICHAUD, B., MISTRY, Y., VAN DAM, A.M., ZHEN, C., DANTZER, R., POOLE, S., ROTHWELL, N.J., TILDERS, F.J., and WOLLMAN, E.E. (1998). Biological activity and brain actions of recombinant rat interleukin-lalpha and interleukin-1beta. Eur. Cytokine Netw. 9, 279-288.
37. SONG, G.Y., DEJONG, G., and JIA, W. (1998). Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type-I. J. Neuroimmunol. 93, 1-7.
38. KONDO, S., MIYATAKE, S., KIKUCHI, H., ODA, Y., IWASAKI, K., OHYAMA, K., and NAMBA, Y. (1992). Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells. Neurosurgery 31, 534-540.
39. YIN, D., KONDO, S., TAKEUCHI, J., MORIMURA, T., NAKATSU, S., ODA, Y., and KIKUCHI, H. (1994). Interferon-gamma induces a decrease in the susceptibility of human glioma cells to lysis by Iymphokine-activated killer cells. Neurosurgery 35, 113-118.
40. MIYATAKE, S., KIKUCHI, H., ODA, Y., NISHIOKA, T., TAKAHASHI, J., KONDOH, S., MATSUMOTO, M., YAMASAKI, T., IWASAKI, K., and AOKI, T. (1990). Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment. Cancer Res. 50, 596-600.
41. MIYATAKE, S., KONDOU, S., AOKI, T., IWASAKI, K., OHYAMA, K., OOTSUKA, S., ODA, Y., and KIKUCHI, H. (1991). Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis. No Shinkei Geka 19, 1053-1059.
42. EDELMAN, G.M., and CROSSIN, K.L. (1991). Cell adhesion molecules: implications for a molecular histology. Annu. Rev. Biochem. 60, 155-190.
43. BALDWIN, T.J., FAZELI, M.S., DOHERTY, P., and WALSH, F.S. (1996). Elucidation of the molecular actions of NCAM and structurally related cell adhesion molecules. J. Cell. Biochem. 61, 502-513.
44. PAUL, D.B., READ, S.B., KULPRATHIPANJA, N., GOMEZ, G.G., KLEINSCHMIDT-DEMASTERS, B.K., SCHILTZ, P.M., and KRUSE, C.A. (2003). γInterferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes. J. Neurooncol. In press.